NEW YORK (GenomeWeb News) – Agilent Technologies yesterday reported a 15-percent increase in third-quarter revenues for its Bio-Analytical Measurement business as deliveries of new products accelerated, the company said.
For the third fiscal quarter ended July 31, Agilent reported $391 million in revenues for the Bio-Analytical business, a 15-percent spike from $341 million in the same quarter last year. The company said it recorded $387 million in orders in Q3, an 11-percent increase from $348 million one year ago.
Agilent said that Life Sciences orders increased 13 percent, while Chemical Analysis orders jumped 10 percent over the year-ago period. The company said that “robust” growth in Asia and Europe was balanced by single-digit growth in the Americas due to ongoing weakness from traditional large pharmaceutical companies.
Agilent Technologies’ total revenues for Q3 increased 17 percent to $1.45 billion from $1.24 billion in the same quarter last year. The company’s net income rose 118 percent to $227 million from $104 million a year ago.
Agilent spent $186 million on R&D in Q3 2006, compared with $183 million in the third quarter of 2005.
As of July 31, Agilent said it had $2.3 billion in cash and cash equivalents on hand.